Weekly Digest - October 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - October 2024
16 Oct 2024: BlissBio receives IND approval from FDA for novel ADC BB-1712
- BlissBio’s investigational new drug application for BB-1712, an antibody-drug conjugate targeting B7-H3, has been approved by the U.S. FDA for treating multiple solid tumors
- Company highlighted the promising preclinical study results for BB-1712, indicating its efficacy and safety, which support moving forward to Phase 1 clinical trials
- BlissBio, founded in 2017 in Hangzhou, is a clinical-stage biotech company focused on developing and commercializing oncology biological therapeutics, with several ADCs currently in clinical trials
- The company emphasizes international collaboration and has the capability to manufacture antibodies and ADCs that meet international GMP standards, aiming to enhance global competitiveness in innovative biologics therapeutics
